Health ❯ Healthcare ❯ Clinical Trials

Cardiovascular Health

Antiplatelet Therapy Heart Failure Cholesterol Management SELECT Study Semaglutide Effects Beta Blockers Lipid-Lowering Therapy Cannabidiol Safety Heart Disease Beta-blocker Therapy Ziltivekimab Cholesterol Atorvastatin Atrial Fibrillation Hypertriglyceridemia Evolocumab PCSK9 Inhibitors Lipid Management Vitamin D3 Treatment Statins Drug Safety Foundayo Trial Results LDL Cholesterol Statin Therapy Risk Assessment Adverse Events Aortic Dissection Pulmonary Hypertension Hypertrophic Cardiomyopathy Lipoprotein(a) Reduction

Orforglipron Found Noninferior to Insulin Glargine for Major Heart Events

The trial establishes cardiovascular safety for the oral GLP‑1 without proving it delivers extra heart protection

Atorvastatin Cuts Major Cardiovascular Events by 30% in Adults 70 and Older

Milvexian Fails to Cut Heart Attack, Stroke or Death After Acute Coronary Syndrome

Aficamten Improves Symptoms and Exercise Capacity in Nonobstructive HCM

Tenax Therapeutics Stock Collapses After Phase 3 Levosimendan Trial Misses Endpoints

Novo Nordisk’s Ziltivekimab Lowers Inflammation but Fails to Reduce Major Heart Events

Single Infusion Gene Editing Lowers LDL by Up to 62% in Early Trial

Lilly’s Oral Foundayo Matches Insulin on Heart Safety in Major Diabetes Trial

Personalized Vitamin D Strategy Halves Risk of Repeat Heart Attack in Randomized Trial

ESC Trials Recast Antiplatelet Strategies After PCI and CABG

Beta-Blockers After Heart Attack Show Mixed Results, Benefit Seen at 40–49% EF

Ionis’ Olezarsen Slashes Triglycerides, Cuts Pancreatitis in Phase 3 Trials

ESC Trials Back Shorter Antiplatelet Therapy for Selected MI Patients